SCHEMBL23745928

SCHEMBL23745928

NC(=O)c1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c2ncnc(N)c12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADK P55263 3/20 0.54
HTT P42858 2/20 0.54
NPC1 O15118 1/20 0.54
GALR3 O60755 1/20 0.54
S1PR4 O95977 1/20 0.54
ALDH1A1 P00352 1/20 0.54
MAPT P10636 1/20 0.54
S1PR1 P21453 1/20 0.54
RAB9A P51151 1/20 0.54
PAX8 Q06710 1/20 0.54
DNMT1 P26358 2/20 0.49
ADRB1 P08588 1/20 0.49
HIF1A Q16665 1/20 0.48
PNP P00491 1/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
PDE4D Q08499 1/20 0.47
PDE3A Q14432 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24127868 1.00 ADK (0.54) ADKHTTNPC1GALR3S1PR4
SCHEMBL6062725 0.93 ADK (0.52) ADKHTTNPC1GALR3S1PR4
SCHEMBL6062721 0.93 ADK (0.52) ADKHTTNPC1GALR3S1PR4
SCHEMBL23743999 0.91 ADK (0.54) ADKHTTNPC1GALR3S1PR4
SCHEMBL24040352 0.85 HIF1A (0.51) ADKHTTDNMT1ADRB1HIF1A
SCHEMBL23743992 0.84 ADK (0.65) ADKHTTNPC1GALR3S1PR4
SCHEMBL17114379 0.84 PRMT5 (0.59) ADKHTTNPC1GALR3S1PR4
SCHEMBL20419182 0.84 PRMT5 (0.59) ADKHTTDNMT1ADRB1HIF1A
SCHEMBL18490333 0.84 ADK (0.52) ADKHTTNPC1GALR3S1PR4
SCHEMBL24313576 0.84 PRMT5 (0.59) ADKHTTDNMT1ADRB1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021211759-A1 METHOD FOR TREATING POXVIRIDAE INFECTIONS OYAGEN, INC. (US) 2021-10-21 WO disclosed
WO-2021158701-A1 METHOD FOR TREATING CORONAVIRUS INFECTIONS OYAGEN, INC. (US) 2021-08-12 WO disclosed